An interventional study of Mandibular advancement device (MAD) and Continuous positive airway pressure (CPAP) in Obstructive Sleep Apnea (OSA), sponsored by University of Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Copenhagen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Sleep Apnea, Obstructive with a site in Denmark — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Denmark.
Among the 26 studies in Sleep Apnea, Obstructive with a site in Denmark, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 25th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →6 of the 26 studies in Sleep Apnea, Obstructive with a site in Denmark are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Denmark, United States, Australia and 7 more countries
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18+
Region Västerbotten · Sites in Denmark, Sweden
Ages 18–75
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark
Ages 18–65 · Healthy volunteers
Regional Hospital West Jutland · Sites in Denmark
Ages 2–12
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 2
First in 1999; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 70 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 51 across the 15 interventional studies, 91 across the 10 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
University of Copenhagen is the lead sponsor of 466 studies on the registry; 64 are open to participants now.
University of Copenhagen has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Sleep Apnea, Obstructive with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnea (OSA) is a frequent illness related to sleep and breathing with many symptoms and complications. The primary choices of treatment are continuous positive airway pressure (CPAP) and removable appliance for protruding the mandible when sleeping (MAD). Treatment with CPAP is superior to treatment with MAD but many patients don't tolerate CPAP why they seek treatment with MAD. In Denmark, treatment with MAD is not free of charge unlike treatment with CPAP and MAD is therefore not offered systematically to the patients. The same applies to adjustment, control and effect of the MAD treatment. MAD treatment has a positive effect on OSA in general but the effect varies due to differences in selection of patients and lack of specifying who performs and evaluates MAD treatment, the effect on sleep and possible side effects in muscles and the temporomandibular joint as well as the occlusion during treatment. It is therefore of great importance to investigate the effect of MAD treatment as well as short- and long-term side effects. The aim is therefore to compare the treatment effect of MAD and CPAP and how significant the investigation of the airways and the face is for the treatment effect and possible side effects. The project is a 4-year investigation and 70 adult patients diagnosed with moderate OSA are included. The results from the investigation will be of great importance for the choice of treatment and prognosis for the individual patient and socio-economic since the treatment of OSA could be tailored the individual patient and the treatment effect optimised.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group starting with the MAD treatment
Device: Mandibular advancement device (MAD) · Device: Continuous positive airway pressure (CPAP)
Group starting with the CPAP treatment
Device: Mandibular advancement device (MAD) · Device: Continuous positive airway pressure (CPAP)
18 months of treatment with MAD in total.
6 months of treatment with CPAP in total.
Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Apnea-Hypopnea Index (AHI)
Defined as the number of apneas and hypopneas per hour of sleep, with higher values indicating greater severity
Time frame: From enrollment to the end of treatment at 24 months
Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Oxygen Desaturation Index (ODI)
Defined as the number of oxygen desaturation events per hour of sleep, with higher values indicating more severe nocturnal hypoxemia
Time frame: From enrollment to the end of treatment at 24 months
Objective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by acoustic pharyngo- and rhinometry
Measured as volume, mean area, minimum cross-sectional area (MCA), distance to MCA and calculated resistance
Time frame: From enrollment to the end of treatment at 24 months
Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Epworth Sleepiness Scale (ESS)
Scale 0-24, higher scores indicate greater daytime sleepiness
Time frame: From enrollment to the end of treatment at 24 months
Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Pittsburgh Sleep Quality Index (PSQI)
Scale 0-21, higher scores indicate worse sleep quality
Time frame: From enrollment to the end of treatment at 24 months
Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Berlin Questionnaire (BQ)
The Berlin Questionnaire classifies individuals as high or low risk for obstructive sleep apnea based on three symptom categories; high risk is defined as having two or more positive categories
Time frame: From enrollment to the end of treatment at 24 months
Subjective treatment effect of MAD and CPAP treatment for treatment of moderate OSA assessed by Short Form 36 (SF-36)
The SF-36 assesses health-related quality of life across eight domains, each scored from 0 to 100, with higher scores indicating better health status
Time frame: From enrollment to the end of treatment at 24 months
The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by lateral cephalogram
Measured with standardized cephalometric angular measurements
Time frame: At baseline and at the end of treatment at 24 months
The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by cone-beam CT (CBCT)
Assessment of upper airway dimensions
Time frame: At baseline and at the end of treatment at 24 months
The significance of DISE and craniofacial morphology for the objective and subjective treatment effect of MAD and CPAP assessed by VOTE-classification
The VOTE classification evaluates obstruction at four anatomical levels (velum, oropharynx, tongue base, epiglottis), with each site scored according to the degree of collapse (0-2), where higher scores indicate greater obstruction
Time frame: DISE is performed before treatment
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by VOTE-classification
The VOTE classification evaluates obstruction at four anatomical levels (velum, oropharynx, tongue base, epiglottis), with each site scored according to the degree of collapse (0-2), where higher scores indicate greater obstruction
Time frame: DISE is performed before treatment.
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by lateral cephalogram
Measured with standardized cephalometric angular measurements
Time frame: At baseline and at the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by cone-beam CT (CBCT)
Assessment of upper airway dimensions
Time frame: At baseline and at the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)
The DC/TMD is applied using both patient-reported symptom questionnaires and a structured clinical examination
Time frame: From enrollment to the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by dental occlusion
Dental occlusion assessed by intraoral scans and number of dental contacts in intercuspidal position (ICP)
Time frame: From enrollment to the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by bite-force
Measured in newtons (N)
Time frame: From enrollment to the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by short-form Oral Health Impact Profile (OHIP-14)
The OHIP-14 assesses oral health-related quality of life across seven domains, with each item scored from 0 (never) to 4 (very often), yielding a total score ranging from 0 to 56, where higher scores reflect greater impairment
Time frame: From enrollment to the end of treatment at 24 months
The significance of DISE and craniofacial morphology for any short- and long-term predictions on side-effects in dental occlusion and oro-facial function during MAD-treatment assessed by Nordic Oro-facial Test-Screening (NOT-S)
The NOT-S consists of 12 domains (6 interview-based and 6 examination-based), each scored as 0 or 1, yielding a total score from 0 to 12, with higher scores indicating more severe orofacial dysfunction
Time frame: From enrollment to the end of treatment at 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2029, 29 months after the start.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 29 months is below that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.